FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295107480> ?p ?o ?g. }

• W4295107480 endingPage "1601" @default.
• W4295107480 startingPage "1592" @default.
• W4295107480 abstract "Abstract Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181, p-tau217 and p-tau231 measured using 10 assays to detect abnormal brain amyloid-β (Aβ) status and predict future progression to Alzheimer's dementia. The study included 135 patients with baseline diagnosis of mild cognitive impairment (mean age 72.4 years; 60.7% women) who were followed for an average of 4.9 years. Seventy-one participants had abnormal Aβ-status (i.e. abnormal CSF Aβ42/40) at baseline; and 45 of these Aβ-positive participants progressed to Alzheimer's dementia during follow-up. P-tau concentrations were determined in baseline plasma and CSF. P-tau217 and p-tau181 were both measured using immunoassays developed by Lilly Research Laboratories (Lilly) and mass spectrometry assays developed at Washington University (WashU). P-tau217 was also analysed using Simoa immunoassay developed by Janssen Research and Development (Janss). P-tau181 was measured using Simoa immunoassay from ADxNeurosciences (ADx), Lumipulse immunoassay from Fujirebio (Fuji) and Splex immunoassay from Mesoscale Discovery (Splex). Both p-tau181 and p-tau231 were quantified using Simoa immunoassay developed at the University of Gothenburg (UGOT). We found that the mass spectrometry-based p-tau217 (p-tau217WashU) exhibited significantly better performance than all other plasma p-tau biomarkers when detecting abnormal Aβ status [area under curve (AUC) = 0.947; Pdiff &lt; 0.015] or progression to Alzheimer's dementia (AUC = 0.932; Pdiff &lt; 0.027). Among immunoassays, p-tau217Lilly had the highest AUCs (0.886–0.889), which was not significantly different from the AUCs of p-tau217Janss, p-tau181ADx and p-tau181WashU (AUCrange 0.835–0.872; Pdiff &gt; 0.09), but higher compared with AUC of p-tau231UGOT, p-tau181Lilly, p-tau181UGOT, p-tau181Fuji and p-tau181Splex (AUCrange 0.642–0.813; Pdiff ≤ 0.029). Correlations between plasma and CSF values were strongest for p-tau217WashU (R = 0.891) followed by p-tau217Lilly (R = 0.755; Pdiff = 0.003 versus p-tau217WashU) and weak to moderate for the rest of the p-tau biomarkers (Rrange 0.320–0.669). In conclusion, our findings suggest that among all tested plasma p-tau assays, mass spectrometry-based measures of p-tau217 perform best when identifying mild cognitive impairment patients with abnormal brain Aβ or those who will subsequently progress to Alzheimer's dementia. Several other assays (p-tau217Lilly, p-tau217Janss, p-tau181ADx and p-tau181WashU) showed relatively high and consistent accuracy across both outcomes. The results further indicate that the highest performing assays have performance metrics that rival the gold standards of Aβ-PET and CSF. If further validated, our findings will have significant impacts in diagnosis, screening and treatment for Alzheimer's dementia in the future." @default.
• W4295107480 created "2022-09-10" @default.
• W4295107480 creator A5015035729 @default.
• W4295107480 creator A5019120747 @default.
• W4295107480 creator A5022462599 @default.
• W4295107480 creator A5025313057 @default.
• W4295107480 creator A5026669710 @default.
• W4295107480 creator A5033218248 @default.
• W4295107480 creator A5041347238 @default.
• W4295107480 creator A5047411304 @default.
• W4295107480 creator A5049277633 @default.
• W4295107480 creator A5051059746 @default.
• W4295107480 creator A5062204294 @default.
• W4295107480 creator A5063370924 @default.
• W4295107480 creator A5068417558 @default.
• W4295107480 creator A5069275587 @default.
• W4295107480 creator A5077992405 @default.
• W4295107480 creator A5091785793 @default.
• W4295107480 creator A5015388641 @default.
• W4295107480 date "2022-09-10" @default.
• W4295107480 modified "2023-10-18" @default.
• W4295107480 title "Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease" @default.
• W4295107480 cites W1683475716 @default.
• W4295107480 cites W1972025839 @default.
• W4295107480 cites W2006617902 @default.
• W4295107480 cites W2028436804 @default.
• W4295107480 cites W2069440543 @default.
• W4295107480 cites W2115017507 @default.
• W4295107480 cites W2795642715 @default.
• W4295107480 cites W2956709519 @default.
• W4295107480 cites W3009441391 @default.
• W4295107480 cites W3009833354 @default.
• W4295107480 cites W3011927235 @default.
• W4295107480 cites W3012272172 @default.
• W4295107480 cites W3014779409 @default.
• W4295107480 cites W3018431352 @default.
• W4295107480 cites W3045987239 @default.
• W4295107480 cites W3045997188 @default.
• W4295107480 cites W3119309452 @default.
• W4295107480 cites W3131174931 @default.
• W4295107480 cites W3152459827 @default.
• W4295107480 cites W3164390524 @default.
• W4295107480 cites W3169529903 @default.
• W4295107480 cites W3174265554 @default.
• W4295107480 cites W3183927686 @default.
• W4295107480 cites W3191044320 @default.
• W4295107480 cites W3194829575 @default.
• W4295107480 cites W3199026337 @default.
• W4295107480 cites W3214939633 @default.
• W4295107480 cites W4200312217 @default.
• W4295107480 cites W4210249852 @default.
• W4295107480 cites W4211213171 @default.
• W4295107480 cites W4213423501 @default.
• W4295107480 cites W4225406326 @default.
• W4295107480 cites W4225972476 @default.
• W4295107480 cites W4280572081 @default.
• W4295107480 cites W4281564421 @default.
• W4295107480 doi "https://doi.org/10.1093/brain/awac333" @default.
• W4295107480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36087307" @default.
• W4295107480 hasPublicationYear "2022" @default.
• W4295107480 type Work @default.
• W4295107480 citedByCount "54" @default.
• W4295107480 countsByYear W42951074802012 @default.
• W4295107480 countsByYear W42951074802022 @default.
• W4295107480 countsByYear W42951074802023 @default.
• W4295107480 crossrefType "journal-article" @default.
• W4295107480 hasAuthorship W4295107480A5015035729 @default.
• W4295107480 hasAuthorship W4295107480A5015388641 @default.
• W4295107480 hasAuthorship W4295107480A5019120747 @default.
• W4295107480 hasAuthorship W4295107480A5022462599 @default.
• W4295107480 hasAuthorship W4295107480A5025313057 @default.
• W4295107480 hasAuthorship W4295107480A5026669710 @default.
• W4295107480 hasAuthorship W4295107480A5033218248 @default.
• W4295107480 hasAuthorship W4295107480A5041347238 @default.
• W4295107480 hasAuthorship W4295107480A5047411304 @default.
• W4295107480 hasAuthorship W4295107480A5049277633 @default.
• W4295107480 hasAuthorship W4295107480A5051059746 @default.
• W4295107480 hasAuthorship W4295107480A5062204294 @default.
• W4295107480 hasAuthorship W4295107480A5063370924 @default.
• W4295107480 hasAuthorship W4295107480A5068417558 @default.
• W4295107480 hasAuthorship W4295107480A5069275587 @default.
• W4295107480 hasAuthorship W4295107480A5077992405 @default.
• W4295107480 hasAuthorship W4295107480A5091785793 @default.
• W4295107480 hasBestOaLocation W42951074801 @default.
• W4295107480 hasConcept C126322002 @default.
• W4295107480 hasConcept C142724271 @default.
• W4295107480 hasConcept C143998085 @default.
• W4295107480 hasConcept C159654299 @default.
• W4295107480 hasConcept C185592680 @default.
• W4295107480 hasConcept C203014093 @default.
• W4295107480 hasConcept C2779134260 @default.
• W4295107480 hasConcept C2779483572 @default.
• W4295107480 hasConcept C2780420688 @default.
• W4295107480 hasConcept C2781197716 @default.
• W4295107480 hasConcept C55493867 @default.
• W4295107480 hasConcept C71924100 @default.
• W4295107480 hasConcept C90924648 @default.
• W4295107480 hasConceptScore W4295107480C126322002 @default.

• next